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Background. The combination antiretroviral therapy (cART) increases the oxidative stress in HIV-infected people, which in turn
favors the onset and aggravation of non-AIDS comorbidities, a common situation affecting these individuals. We aimed to evaluate
the influence of cART initiation on oxidative stress parameters. This is a longitudinal study including 30 asymptomatic patients
divided according to their CD4+ T cell count (G1: <500 cell/mL; G2: >500 cell/mL) before (M0) and after (M1) cART initiation.We
analyzed total antioxidant capacity (TAC), fat-soluble vitamins,malondialdehyde, 8-isoprostane, andDNAdamage.Results. Results
showed a decrease in TAC, retinol, 𝛼-tocopherol, and some carotenoids, in addition to a significant increase in DNA damage at
M1. These changes were more evident in G2 subjects. Moreover, there was a significant 8-isoprostane increase at M1 in individuals
belonging to G1. Conclusion. The results indicate that cART interfered in the redox system, mainly by reducing the antioxidant
defenses. In addition, patients who had CD4+ T counts higher than 500 cells/mm3 showed more susceptibility to genotoxicity,
while patients with less CD4+ T counts displayed more damage triggered by lipoperoxidation. Considering the early beginning of
cART, its chronic use, and its capacity to alter the redox status, further long-term studies on larger cohorts are needed to define the
best time to initiate therapy and to investigate new strategies to delay the development of non-AIDS diseases.
1. Introduction
Nowadays, there is increasingly early recommendation for
therapeutic beginning in HIV-infected people, a strategy to
promote benefits in patients and to reduce transmission rates
[1–3]. However, due to prolonged use of antiretroviral therapy
(cART), its toxic effects should be taken into account. In
addition to kidney, liver, and bone impairment, many drugs
are responsible for the onset of the metabolic syndrome and
consequently for the increase of non-AIDS comorbidities,
what could be contributing to current causes of death in
this population such as cardiovascular disease and diabetes
mellitus, among others [1, 4–6].
cART also seems to contribute to the imbalance between
oxidants and antioxidants agents in people living with
HIV/AIDS (PLWHA) by increasing the former and decreas-
ing the latter [6–9]. Such oxidative stress results in dysregula-
tion of signaling and redox control, possibly leading tomolec-
ular damage [10]. As a result of this process, genotoxic and
mutational effects contributing to the development of cancer
and other non-AIDS diseases may occur [11, 12], and such
homeostatic instability could even accelerate the progression
of HIV infection to AIDS [12], even this relationship being
speculative.
The literature points out that lipid peroxidation, as mea-
sured, for example, by serum analysis of malondialdehyde
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(MDA) [13, 14] and 8-isoprostanes [6, 15], is higher in
PLWHA, compared to noninfected individuals [13, 14], and
it increases following cART initiation [6, 15]. In addition, a
recent study with these markers has shown that oxidative
stress was a predictor of all-cause mortality in HIV-infected
patients, and, for F2-isoprostane, this association is inde-
pendent of HIV-related factors and subclinical inflammation
[16]. Further, HIV-individuals under cART have less total
antioxidant capacity (TAC) [17] and a lower vitamin profile
[8, 18] as compared to patients na¨ıve to treatment. Thus not
only the pathogenesis of HIV but also therapy may influence
the increase in prooxidants and the decrease in antioxidants
in PLWHA, leading to consequent damage to important
biomolecules as lipids, protein, and nucleic acids [9, 19, 20].
For this reason we hypothesized that cART can increase
the oxidative status of PLWHA already in the initial months
of treatment, which could occur differently in patients,
according to their pre-cART CD4+ T counts.
The objective of this study was to analyze the influence
of cART initiation on oxidative stress parameters in asymp-
tomatic HIV-infected individuals.
Compared to previous studies that have already inves-
tigated some of these markers, this study will take into
consideration all of these parameters in the same cohort,
in a strictly controlled population (without comorbidities,
coinfections, or habits that could influence the marker levels)
and relative to different CD4+ T cells before therapeutic
onset. Moreover to our knowledge, no previous studies
investigated the nuclear DNA damage by comet test in this
population under the given conditions.
2. Material and Methods
2.1. Study Design. This longitudinal study was conducted
between 2012 and 2015, on 30 HIV+ patients who attended
at the Specialist Outpatient Service for Infectious Diseases
“Domingos Alves Meira,” at the Botucatu Medical School
Complex (FMB)-UNESP, in Sa˜o Paulo state, Brazil. This
Service covers about 600 HIV-infected people from Botu-
catu and surrounding area; for this study, 150 consecutive
antiretroviral treatment-na¨ıve patients were interviewed, but
only 30 of them were included according to the exclusion
criteria.
Data collection and biological samples were carried out in
two stages: before therapy initiation (M0) and approximately
eight months after that intervention (M1), when the sec-
ond medical appointment was conveniently scheduled and
comprised between 30 and 48 weeks. This second period of
analysis was given appropriate, considering the high unde-
tectability rates observed in our service combined with the
data presented in the “Guidelines for theUse of Antiretroviral
Agents in HIV-1-Infected Adults and Adolescents-2014”:
“Individuals who are adherent to their ARV regimens and
do not harbor resistance mutations to the component drugs
can generally achieve viral suppression 8 to 24 weeks after
ART initiation; rarely, in some patients it may take longer”
[21].
In Brazil, as well as in some other countries, the current
recommendation by the Ministry of Health is that cART
should be offered to all HIV-infected patients, regardless
of CD4+ T counts [2]. However, until December 2013,
the treatment was indicated only for asymptomatic indi-
viduals with CD4+ T counts below 500 cells/mL. There-
fore, in our study, patients were also divided according to
their pre-cART CD4+ T cell count, (G1: <500 cells/mL; G2:
>500 cells/mL).
2.2. Inclusion and Exclusion Criteria. PLWHA inclusion cri-
teria were age comprised between 20 and 50 years old, no
previous cART administration, and signing an Informed
Consent Form.
Considering many habits and comorbidities could be
confounding variables and would interfere in our analysis of
oxidative stress [22], patients carrying any of the following
conditions were excluded: use of vitamin supplements, can-
cer history (current or previous), anorexia, morbid obesity,
diabetes mellitus, cardiovascular, genetic or autoimmune
diseases, organ transplants, use of illicit drugs and alcohol,
pregnancy at any stage or breastfeeding, AIDS symptoms
(those with opportunistic infections), or coinfections such as
tuberculosis or chronic viral hepatitis.
For the following criteria, exclusion occurred when
patients concomitantly reported two of themormore: regular
performance of intense physical exercise; use of antibiotics,
anxiolytics, or antidepressants; active smoking. People with
only one of these conditions were included because the
statistical analysis was adjusted for these variables.
2.3. Sociodemographic and Clinical Data. Sociodemographic
and clinical data were collected by interviews and from the
patients’ medical records, taking into account the date of
blood collection for this study.
2.4. Analyses of Oxidative Stress Parameters. Twelve milli-
liters of blood was collected into an EDTA containing tube
from each patient included in the study. The material was
maintained in a cooled and dark environment for 2-3 hours.
After that, 60𝜇L of total blood was separated for the comet
assay procedure and the remaining sample was centrifuged at
1,500 rpm for 10 minutes. Six plasma aliquots per individual
were stored at −80∘C until the tests were performed. We ana-
lyzed the following variables: lipid peroxidation (MDA and
8-isoprostane), DNA damage, TAC and vitamin profile with
dosages of carotenoids (lutein, cryptoxanthin, 𝛽-carotene,
and lycopene), retinol, and 𝛼-tocopherol.
(i) Measurement of Lipid Peroxidation by Analysis. The high
performance liquid chromatography (HPLC) technique was
performed by using the Shimadzu HPLC System according
to the Nielsen et al. method [23], with 100𝜇L of plasma. For
quantification of chromatograms, a comparison between the
substance and the pattern area was made, and results were
expressed by 𝜇mol/L.
(ii) Evaluation of Lipid Peroxidation by Analysis of 8-
Isoprostane. The immunoenzymatic assay (ELISA) was
performed according to the manufacturer’s instructions
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Table 1: Characterization of 30 PLWHA studied.
Variables MEAN (±SD) or %
General M0 M1
Age (years) 34 (±8.2) — —
Male gender 60.0% — —
Smokers# 30.0% — —
Physical activities practice# 23.3% — —
Use of anxiolytics or antidepressants# 6.6% — —
Time since HIV diagnosis (years) 2.2 (±3.2) — —
post-cART follow up period (months) 8.1 (±1.4)
cART regimen: NRTI + NNRTI 83.3% — —
cART regimen: NRTI + PI/r 16.7%
CD4+ T nadir (cells/mL) 335.7 (±211.3) — —
% of patients presenting CD4+ T <500 cells/mL — 70.0% 86.6%
CD4+ T counts (cells/mL) — 454.69 (±136.4) 625.07 (±276.9)∗
Undetectable HIV viral load — 3,3% 80.0%∗
SD: standard deviation; PLWHA: people living with HIV/AIDS; cART: combined antiretroviral therapy; M0: before cART initiation; M1: after cART initiation;
NRTI: nucleoside reverse-transcriptase inhibitors; NNRTI: nonnucleoside reverse-transcriptase inhibitors; PI/r: protease inhibitors reinforced with ritonavir;
# isolated presence of these cited factors (which were not excluded, due the adjustment of statistical analysis fulfilled). Statistical tests: Gamma Distribution
and ANOVA, ∗𝑝 < 0,001.
(Cayman, item 516351) using 50 𝜇L of plasma. Optical den-
sities were calculated in pg/mL.
(iii) Analysis of DNA Damage in Peripheral Blood Mononu-
clear Cells by Comet Assay. It was developed according to
Sasaki et al. [24] using 30𝜇L of whole blood set on a blade
with agarose. After lysis solution treatment, triplicates of the
blades were subjected to three different conditions in elec-
trophoresis: basal condition (BAS), formamidopyrimidine
DNA glycosylase (FPG), or endonuclease III (END) addition
for detection of oxidative damage in purine and pyrimidine
bases, respectively (Biocompare, CA, USA). The slides were
stained by Sybr Gold (Invitrogen, USA). Using an immunoflu-
orescence microscope connected to an image analysis system
(comet assay IV, Perceptive Instruments, Sufolk, Haverhill,
UK), a total of 50 randomly selected nucleoids were counted
for each slide. Results were expressed as “tail intensity” (ti),
which is the percentage of migrated DNA, and “tail moment”
(tm), relative values from the fraction of migrated DNA
multiplied for the length of the tail.
(iv) Analysis of the TAC. Using 100 𝜇L of plasma, it was
determined calorimetrically in triplicate according to the
methodology described by Beretta et al. [25] using the
VICTOR X2 reader (Perkin Elmer, Boston, MA, USA). Results
were expressed as % of protection.
(v) Fat-Soluble Vitamins. They were measured from 100 𝜇L
of plasma by HPLC (Waters 2996), by a C30 column (150 ×
4.6mm, 3𝜇m) and according to Ferreira andMatsubara [26].
The wavelength used was 455 nm for carotenoids (lutein,
cryptoxanthin, lycopene, and 𝛽-carotene), 325 nm for retinol,
and 290 nm for 𝛼-tocopherol. The values of the standard
solution of the substanceswere fixed by theirmolar extinction
coefficients expressed in 𝜇mol/mL.
2.5. Analysis of Results. We used a generalized linear model
with Poisson or Negative Binomial distribution for count
variables and Gamma Distribution for asymmetric variables
or One-way ANOVA followed by Tukey-Kramer post hoc
tests for those symmetric data in a repeated measure design
testing a “moment versus group” interaction. Pearson corre-
lations were adopted to analyze continuous variables.
After fitting the model, confounding variables (age, sex
and tobacco use, practice of intense physical activity, and
use of anxiolytics and/or antidepressants) were added in
order to verify their influence on the “moment versus group”
interaction, as is done in a covariance analysis model.
Significant differences were considered when 𝑝 values
were less than or equal to 0.05. All these procedures were
performed with help from professionals at the institution’s
Research Support Office using SAS for Windows, version 9.2
(PROCMIXED and PROC GENMOD).
This study was approved by the Research Ethics Commit-
tees of the Botucatu Medical School (Faculdade de Medicina
de Botucatu), protocol number 4327-2012.
3. Results
The enrolled individuals was primarily male (60%), aged
between 20 and 49 years (34 ± 8.2) and most of the patients
were diagnosed HIV-positive less than three years ago. The
sociodemographic, clinical, and epidemiological characteris-
tics of the subjects included in the study are shown in Table 1.
About eighty percent of patients started cART with first-
line regimens which are composed of two NRTIs and one
NNRTI. In the second blood collection (M1), 80% of the
participants had undetectable viral load.
The evaluation of CD4+ T cell counts in M1 showed an
increase in relation to M0 (𝑝 < 0.0001), which was more
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Figure 1: Means of MDA, 8-isoprostane, and TAC of 30 PVWHA before (M0) and after (M1) cART initiation. In blue: patients analyzed
together; in red: patients separated into initial CD4+ T groups. G1- CD4+ T counts <500, 𝑛 = 11; G2- CD4+ T >500 cells/mL (considering
the counts in M0), 𝑛 = 19. PLWHA: people living with HIV/AIDS; cART: combined antiretroviral therapy; MDA: malondialdehyde; TAC:
total antioxidant capacity; statistical tests: Gamma Distribution for MDA and 8-isoprostane and ANOVA with post hoc Tukey tests for the
TAC. ∗𝑝 < 0.05.
evident in G1 compared to G2 (respective gain in cell counts:
209.71, versus 109.62 cells/mL).
No differences were observed inMDA (M0: 1.7±0.9; M1:
1.5 ± 1.0 𝜇mol/mL) or 8-isoprostane levels (M0: 42.0 ± 24.7;
M1: 54.2± 49.8 pg/mL) after cART initiation; conversely, TAC
decreased significantly after cART initiation (M0: 61,8±12.3;
M1: 45.7 ± 7.4%; 𝑝 < 0.001). In a separate analysis by groups
of G1 and G2 patients, there was no difference in MDA
comparing M0 and M1. As for 8-isoprostane G1 subjects
showed an increase after cART initiation (𝑝 = 0.011). For
TAC, both groups showed differences between M0 and M1
(G1: 𝑝 < 0.001; G2: 𝑝 = 0.016) (Figure 1).
As for carotenoids, we observed a decrease in lycopene
(𝑝 = 0.015), 𝛽-carotene (𝑝 < 0.0001), 𝛼-tocopherol (𝑝 =
0.005), and retinol levels (𝑝 = 0.0021) inM1 compared toM0.
After cART we observed a reduction in lutein (𝑝 = 0.018)
and lycopene levels (𝑝 = 0.019) only in G2 group and in
𝛽-carotene (𝑝 < 0.010) and 𝛼-tocopherol (𝑝 < 0.050) in
both G1 and G2 (Table 2). We also categorized the results of
vitamins considering reference values previously established
by Kaio et al. [8] (<1.0 for 𝛽-carotene, <0.7 𝜇mol/L for
retinol and <16.0 𝜇mol/L for 𝛼-tocopherol). The percentages
of individuals with values below the ideal, prior to therapeutic
initiation, were 93%, 17%, and 60% for 𝛽-carotene, retinol,
and 𝛼-tocopherol, respectively.These proportions changed to
100%, 7%, and 90% after cART.
In relation to the comet assay, there was a slight increase,
although not significant, for the “tail moment” (𝑝 = 0.068)
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Table 2: Vitamin profile of 30 PLWHA before (M0) and after (M1) cART initiation.
Variables M0 (MEAN ± SD) M1 (MEAN ± SD) 𝑝 value
Lutein (𝜇mol/mL)# 0.06 ± 0.06 0.05 ± 0.04 Ns
G1 0.06 ± 0.06 0.05 ± 0.04 Ns
G2 0.06 ± 0.04 0.04 ± 0.03 0.018
Cryptoxanthin (𝜇mol/mL)# 0.08 ± 0.09 0.07 ± 0.07 Ns
G1 0.07 ± 0.05 0.07 ± 0.08 Ns
G2 0.15 ± 0.14 0.07 ± 0.05 Ns
𝛽-Carotene (𝜇mol/mL)# 0.31 ± 0.39 0.17 ± 0.12 <0.0001
G1 0.28 ± 0.36 0.15 ± 0.10 0.002
G2 0.31 ± 0.44 0.18 ± 0.17 0.001
Lycopene (𝜇mol/mL)# 0.66 ± 0.47 0.44 ± 0.24 0.015
G1 1.94 ± 3.98 0.45 ± 0.22 Ns
G2 0.86 ± 0.58 0.32 ± 0.26 0.019
𝛼-Tocopherol (𝜇mol/mL)# 17.94 ± 8.37 4.14 ± 5.72 0.005
G1 15.82 ± 8.52 4.29 ± 5.85 0.030
G2 18.78 ± 10.53 3.85 ± 6.19 0.048
Retinol (𝜇mol/mL)# 2.83 ± 1.42 1.82 ± 0.49 0.002
G1 2.47 ± 1.41 1.86 ± 0.51 Ns
G2 2.78 ± 1.75 1.36 ± 0.48 Ns
PLWHA: people living with HIV/AIDS; cART: combined antiretroviral therapy; G1- CD4+ T counts <500, 𝑛 = 11; G2- CD4+ T >500 cells/mL (considering
the counts in M0), 𝑛 = 19; SD: standard deviation; Ns: no significant values; # analysis of the 30 total patients without division into groups. Statistical tests:
ANOVA with post hoc Tukey tests for retinol and Gamma Distribution for the other variables.
and “tail intensity” (𝑝 = 0.097) relative to slides treated with
END in M1 compared to M0. However, when analyses were
performed considering the G1 and G2 groups, we observed
an increase in DNA damage only in G2, at the “tail moment”
of the blades treated with FPG (𝑝 = 0.032) and END (𝑝 =
0.050), and in the “tail intensity” of the blades treated with
END (𝑝 = 0.012). These data are shown in Figures 2(a) and
2(b).
Additionally, we found a positive correlation between
MDA and plasma HIV viral load (VL) (𝑟 = +0.5858, 𝑝 <
0.001). Negative correlations occurred between retinol and
VL (𝑟 = −0.3821, 𝑝 = 0.033), between 𝛼-tocopherol and
END-ti (𝑟 = −0.6917, 𝑝 = 0.001) and END-tm (𝑟 = −0.6182,
𝑝 = 0.006), between lycopene and BAS-tm (𝑟 = −0.4582,
𝑝 = 0.028) and between END-ti with lutein (𝑟 = −0.5505,
𝑝 = 0.018), cryptoxanthin (𝑟 = −0.6480, 𝑝 = 0.004) and 𝛽-
carotene (𝑟 = −0.5508, 𝑝 = 0.017). No correlation was found
between the adopted antiretroviral regimens (PI × NNRTI)
and the variables studied in this investigation.
4. Discussion
HIV infection is characterized by severe immunodeficiency,
a consequence of numerical and functional CD4+ T cell
depletion [3]. The patients enrolled in this study showed
an increase in CD4+ T cell count after cART initiation
(450 versus 625 cells/mL) and 80% of them attained VL
undetectability, consistent with an improvement in immune-
virological parameters. There is no doubt about the benefits
of cART in reducing morbidity and mortality in AIDS [1,
3], but its long-term use is related to many adverse events
specially the increase of metabolic disorders and oxidative
stress, factors that contribute to the development of non-
AIDS comorbidities [4, 5, 19].
It is known that the therapy in some individuals may
affect mitochondrial morphology and function [27] and the
activation of the P450 cytochrome enzyme system [6], which
in turn increases the reactive oxygen (ROS) and nitrogen
(RNS) species in circulation.The generation of free radicals as
well as the intense consumption and the absence/deficiency of
antioxidants are responsible for damaging proteins, cells, and
tissues [19]. In addition, cART is associated with metabolic
disorders that increase oxidative stress in infected individuals
[19]. All of this can lead to the chronic inflammatory status
that these patients often present.
Additionally, as demonstrated by our own group in a
recent research employing the same cohort of the present
study, although there was no difference in the levels of some
inflammatory and anti-inflammatory cytokines, there was an
increased level of C-reactive protein (CRP) and triglycerides
already in the firstmonths of therapy [28].Thesemarkersmay
also be associated with increased oxidative stress described
here in the same period.
Differences in MDA values, a product of lipid peroxida-
tion, were not observed here between pre- and post-cART
treatment, nor in relation to initial CD4+ T counts. We
just observed a positive correlation between VL and MDA,
suggesting the influence of viral pathogenic effects on the
increase of oxidative stress. However there are controversial
data on this marker in literature. While some authors [29]
showed no differences between HIV-infected or uninfected,
symptomatic or asymptomatic patients, others [14, 30] have
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Figure 2: DNA damage of 30 PVHA, before (M0) and after (M1) cART initiation. (a)→ In blue: patients analyzed together; in red: patients
separated into initial CD4+ T groups. G1- CD4+ T counts <500, 𝑛 = 11; G2- CD4+ T >500 cells/mL (considering the counts in M0), 𝑛 = 19.
PLWHA: people living withHIV/AIDS; cART: combined antiretroviral therapy. BAS: basal condition (without enzymes); END: blades treated
with the endonuclease III enzyme (thymine glycol -DNA glycosylase); FPG: blades treated with the formanodipirimidina-DNA glycosylase
enzyme. Statistical tests: Gamma Distribution for Bas-ti and FPG-tm; ANOVA with post hoc Tukey tests for the other variables. ∗𝑝 < 0.05.
Units of measure: ti (tail intensity) and tm (tail moment). (b)→This HIV-infected subject presented initial CD4+ T counts >500 cells/mL,
and the figure shows the enzymatic (END [A, B], FPG [C, D]) and basal conditions (BAS [E, F]), before (A, C, E) and after (B, D, F) cART
initiation.
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found higher MDA concentration in infected patients with
low CD4+ T counts.
Another marker of oxidative stress based on lipid per-
oxidation is PGF2 alpha-8-isoprostane or 8-isoprostane,
the most abundant compound among F2-isoprostanes. We
showed no changes in their levels after therapeutic inter-
vention, when patients were analyzed together. However, G1
group showed a significant increase in 8-isoprostanes levels
in M1 compared to M0. Hulgan et al. [6] also found elevated
plasma concentrations of F2-isoprostane in PLWHA under
cART and viral suppression. Crist et al. [31] showed higher
8-isoprostane levels in HIV-infected women as compared to
men; therefore it is worth mentioning that, in our study, the
analysis was adjusted for gender, age, and other variables that
could be confounding.
In relation to the pharmacological treatment, the 16.7%
of patients receiving IP/r were taking lopinavir/ritonavir and
almost all of the 83.3% of individuals who received NNRTI
were taking efavirenz; nevertheless we did not find any
correlation between antiretroviral classes and the levels of
the analyzed parameters, perhaps due to the short period of
therapy using. In this regard, Hulgan et al. [6] and Gupta et
al. [32] showed that F2-isoprostane levels increase in subjects
under efavirenz as compared to those under rilpivirine, a
second-generation NNRTI. Different plasma levels of this
marker were also found by Redhage et al. [15] in a drug
scheme comparison, showing higher, intermediate, and lower
levels in NNRTI-free, treatment-naı¨ve, and NNRTI-treated
patients, respectively. High concentrations of F2-isoprostanes
were also observed in relation to other chronic diseases
and habits, such as atherosclerosis [33], Alzheimer [34], and
smoking [35], in HIV-uninfected individuals. Thus, there is
need for better understanding this and other markers in the
pathogenesis of HIV and non-AIDS-related diseases.
The production of an effective antioxidant system is
needed, in order to control this repertory of prooxidants.
Human cells are fraught with endogenous and exogenous
antioxidants, enzymatic and nonenzymatic [36]. The mea-
surement of TAC considers the cumulative effect of all
antioxidants present in blood and body fluids, considering
both lipophilic and hydrophilic compartments [25, 37].
In the present study, a decrease in TAC occurred after
cART initiation, and these data have been corroborated by
other studies [17, 19]. This decrease was independent from
the initial CD4+ T cell count; however Suresh et al. [13]
showed a lower TAC in HIV-naı¨ve patients than uninfected
individuals, and this decrease was more accentuated in
those with CD4+ T cells below 500/mL. PLWHA with the
metabolic syndrome also showing a decline in TAC, which
was independent of the presence of cART [19]. However, the
findings byMandas et al. [17] showed that oxidative stress was
higher in patients who adhered to therapy as compared to
nonadherents, reinforcing the role of antiretroviral drugs in
the induction of these mechanisms.
One of the explanations for low TAC in PLWHA would
be the high consumption of antioxidants due to high levels
of ROS presented by this population [14]. The other would
be the lack of antioxidant intake and of their precursors
and/or the poor absorption of nutrients resulting from the
changes in intestinal homeostasis [14, 38]. Aspects related to
dietary surveys and clinical manifestations suggestive of the
malabsorption syndromewere not assessed in this study; thus
comparisons were not possible. Therefore, it is important to
investigate which components of the antioxidant system are
deficient in this population.
Carotenoids have been studied over the years not only for
their proven pro-vitaminA activity, but also for their capacity
to modulate T cell proliferation, Th17 and regulatory T cell
activity in the gut, and production of local immunoglobulinA
[39]. Furthermore carotenoids were proven to reduce the risk
of degenerative diseases, including certain types of cancer and
cardiovascular diseases [40]. Herein, after cART initiation
we observed a decrease in lutein, 𝛽-carotene, lycopene, and
retinol levels, which was more evident in the G2 group.These
results resemble those reported by other authors [18, 41]
which found a 98% 𝛽 carotene deficiency and 4% retinol
deficiency in treated PLWHA; indeed in our cohort 100% of
patients had disabilities to 𝛽- carotene, and only 6.6% showed
retinol deficiency after eight months of cART initiation (data
not shown). Based on these data, we share the conclusions of
those authors [18] suggesting that PLWHAwould not benefit
from vitamin A supplementation, but from 𝛽-carotene, as its
antioxidant effect could be more beneficial for individuals on
cART.
The most abundant active compound of vitamin E, 𝛼-
tocopherol, also plays an essential role in antioxidant pro-
tection as it prevents propagation of lipid peroxidation and
reduces damage caused by free radicals [12]. Furthermore, it
is related to the reduction of proinflammatory cytokines [39].
Some studies [13, 42] on naı¨ve HIV-infected individuals have
shown that the deficiency of this and other micronutrients
occurred more significantly in patients with lower CD4+ T
counts. In our study, 𝛼-tocopherol showed low levels after
cART initiation independently from initial CD4+ T cell
count.
Another study by Kaio et al. [8] compared 𝛼-tocopherol
levels with antiretroviral classes and showed a decrease of
this vitamin in nearly 20% of PLWHA [8]. Conversely in our
study approximately 60% and 90% of the PLWHA showed
𝛼-tocopherol deficiency before and after cART introduction,
respectively (data not shown). Nevertheless, the participants
in both studies were from the same region and the same
Brazilian state; thus it can be assumed that the populations
share similar habits such as diet. In an attempt to justify
the difference between these results, it is necessary to con-
sider some aspects. In the cross-sectional study by Kaio
et al. [8], at the time of enrollment patients have already
been using cART for an extended period, for nearly 10
years, and they had received more than one therapeutic
scheme, including therapeutic rescue. On the other hand,
in our longitudinal study treatment duration was only eight
months on average, and most patients were receiving the
first scheme composed of NNRTI which could reduce 𝛼-
tocopherol levels. We could also presume that there may be
a greater loss/consumption/deficiency of this vitamin in the
first months of therapy in relation to its prolonged use.
As a result of this imbalance between pro- and antiox-
idants, some genotoxic alterations may occur, therefore we
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decided to analyze the DNA damage by comet assay. When
the patients were analyzed together, we could not observe
any significant difference between M0 and M1; conversely
increased oxidative genotoxic damage was detected in the
group with higher CD4+ T cell count, which could be
explained at least in part by the toxicity of cART. To our
knowledge, there are no studies assessing DNA damage by
comet assay in blood of HIV-infected asymptomatic individ-
uals before and after cART. Aukrust et al. [43] reported that
DNA glycosylase, a genomic damage repair marker, showed
an inverse correlation with VL and increased of CD4+ T
cell levels in individuals who used cART for six months.
The same authors [43] showed a reduction in 8-oxoG (7,8-
dihydro-8-oxoguanine), a marker of oxidative DNA damage,
in CD4+ T cells from subjects with cART as compared to
naı¨ve individuals.
de Oliveira et al. [44] showed genotoxic effects in the
brains of mice chronically treated with efavirenz and sug-
gested that DNA damage was induced by oxidative stress,
which could also explain the neuropsychiatric effects of drug
use. However, cART is not the only responsible for increasing
the frequency of genotoxic damage in PLWHA. The tat
HIV protein, due to the generation of superoxide anion by
mitochondria, induces intracellular ROS production. They,
in turn, activate NF-𝜅B, thus increasing HIV transcription
[6], genomic instability, and deficiency in DNA repair, which
results in higher mutation rate favoring the onset of cancer
[12].
We have to consider some limitations in our study such
as a small sample size and, as this was not an interventional
randomized trial, it is possible to establish only associations
but not cause-effect relationships between variables. Besides
that, although our aim was to check the marker’s changes
in the therapeutic beginning, the short cART duration (only
eight months) could not reflect the effects of long-term
therapy use and the variability of cART duration among the
participants (30–48 weeks) could be one of the factors for
the few findings in this study compared to we expected.
Other biases are related to the absence of dietary surveys
or anthropometric measurements in our patients, which
could be interesting mainly for analysis of healthy food
consumption and dosages of vitamins related here; the lack
of a control group, which would allow us to compare the
baseline levels of the parameters chosen in non-HIV-infected
individuals; and the TAC biomarker choice, because it is a
very nonspecific antioxidant index, which does not refer to
any specific pathway. Despite these limitations the studied
population underwent rigorous exclusion criteria in order to
minimize possible confounding effects in the results.
Our next step is to follow this cohort and analyze these
parameters in the future to investigate whether this initial
oxidative stress would be altered according to years of cART
administration.
5. Conclusion
On the whole our results suggest that increased oxidative
stress results not only from a direct viral involvement but
also fromcARTadministration,which considerably increases
such stress in infected asymptomatic HIV-infected individu-
als already in the first months of therapy.
Indeed, cART seems to increase the production of some
prooxidants, such as 8-isoprostane and probably others not
measured here, which would diminish TAC, including the
carotenoids and vitamin profile. This disturbance in turn
would contribute to an imbalance between oxidants and
antioxidants and, consequently, to a more sustained geno-
toxic damage in treated patients, mainly in those with high
values of CD4+ T pretherapy (>500 cells/mL).
Therefore, despite the evident benefits of treatment, there
is a need for further studies with larger cohorts and more
discussion about the best time to begin cART, especially for
HIV-infected individuals who are long-term nonprogressors,
and those uninfected that choose to take the preexposure
prophylaxis. Studies proposing dietary interventions and/or
nutrition education, could also contribute to the reduction of
oxidative stress and the consequent persistent inflammation.
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